前列腺特异抗原和P504S在前列腺癌中的表达及其临床意义

doi:10.3969/j.issn.1671-7171.2021.06.028

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1116 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the expression and clinical significance of PSA and P504S in prostate cancer. 【Methods】 A total of 62 cases of prostate cancer and 32 cases of benign prostatic hyperplasia from May 2018 to May 2020 were selected for the study. The expression of P504S and PSA in prostate cancer tissues was detected by immunohistochemistry. The relationship of PSA and P504S expression with clinical pathological characteristics was analyzed. 【Results】The positive expression rates of P504S and PSA in prostate cancer were 93.55% (58/62) and 90.32% (56/62), which were significantly higher than their 0% (0/32) and 3.13% (1 /32), and the differences between the two groups were significant (all P<0.05). The positive expression of P504S and PSA in prostate cancer and benign prostatic hyperplasia was significantly different (P<0.05).The positive expression rate of P504S and PSA in prostate cancer increased with the increase of pathological grade, and the difference was statistically significant (P<0.05).In prostate cancer, the expression of P504S and PSA in high stage was significantly higher than that in low stage (P<0.05). The expression of PSA decreased in prostate cancer patients with higher Gleason score. While the expression of P504S increased with higher Gleason score. The difference was statistically significant (P<0.05). 【Conclusion】The expression levels of P504S and PSA can properly reflect the biological behavior of prostate cancer.

Key words： Prostatic Neoplasms/PA Prostate-Specific Antigen

Received: 14 October 2020

PACS:

R737.25

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SONG Ya-dong
	LI Ping

Cite this article:

SONG Ya-dong,LI Ping. Expression and Clinical Significance of PSA and P504S in Prostate Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(6): 903-905.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2021.06.028 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2021/V38/I6/903

[1] 魏灿, 张艳斌, 应全胜, 等.乳腺癌转移抑制基因和骨桥蛋白在前列腺癌组织的表达及其临床意义[J].中华实验外科杂志, 2018, 35(12):2193-2195.
[2] VIGNESHWAR, SUBRAMANIAN, MICHAEL, et al.Prostate cancer:Numeracy and understanding of risk reduction of PSA screening.[J].Nat Rev Urol,2018,15(4):208-209.
[3] 梁静, 赵晓智, 时静妍, 等.南京地区前列腺癌筛查“PSA-mpMRI-靶向穿刺”模式的初步探索[J].中华男科学杂志, 2019,24(9):815-822.
[4] 孙超, 刘丽辉, 王学民, 等.蛋白磷酸酶2A的癌性抑制因子在前列腺癌细胞增殖、凋亡和侵袭中的作用[J].中华实验外科杂志, 2019, 36(2):343-345.
[5] RABBANI F,REUTER VC,KATZ J,et al.Second primary malignancies associated with renal cell carcinoma:influence of histologic type[J].Urology,2000,56(3):399-403.
[6] REBECCA KELSEY.Prostate cancer:Solo PSA test does not lower mortality[J].Nat Rev Urol,2018,15(5):262-263.
[7] 张伟, 褚菁, 邹玉玮, 等.延胡索酸水合酶缺陷型肾细胞癌的临床病理学特征[J].中华病理学杂志, 2019, 48(2):120-126.
[8] 赵劲歌, 聂玲, 陈雪琴,等.前列腺导管内癌对转移性前列腺癌各亚组患者的预后影响[J].中华外科杂志, 2019, 57(6):422-427.
[9] TIMOTHY J W, PAULINE J W, ANDREW S.Thompson,et al.Chiral inversion of 2-arylpropionyl-CoA esters by human a-methylacyl-CoA racemase 1A (P504S)-a potential mechanism for the anti-cancer effects of ibuprofen[J].Chem Commun,2011,47(26):7332-7334.
[10] 王凯,曲弘辰,谢庆鹏, 等.前列腺癌组织中P504S蛋白表达变化及其临床意义[J].肿瘤药学,2019,09(1):90-93.
[11] 张莹,王希喆,周露, 等.p504s、ck5/6和p63表达水平在前列腺增生和前列腺癌中的诊断价值[J].中国医药导报,2018,15(17):106-109.
[12] 毕罡,毛成毅,江军, 等.联合检测P504s和Claudin-4在前列腺癌中的表达及其在预后评估中的价值[J].第三军医大学学报,2019,41(22):2195-2198.